TY - JOUR AU - Kappéter, Ágnes AU - Sipos, Dávid AU - Varga, Adorján AU - Vigvári, Szabolcs József AU - Halda-Kiss, Bernadett AU - Péterfi, Zoltán TI - Migraine as a Disease Associated with Dysbiosis and Possible Therapy with Fecal Microbiota Transplantation JF - MICROORGANISMS J2 - MICROORGANISMS VL - 11 PY - 2023 IS - 8 PG - 14 SN - 2076-2607 DO - 10.3390/microorganisms11082083 UR - https://m2.mtmt.hu/api/publication/34095174 ID - 34095174 N1 - ISSN:2076-2607 AB - Migraine is a painful neurological condition characterized by severe pain on one or both sides of the head. It may be linked to changes in the gut microbiota, which are influenced by antibiotic use and other factors. Dysbiosis, which develops and persists as a result of earlier antibiotic therapy, changes the composition of the intestinal flora, and can lead to the development of various diseases such as metabolic disorders, obesity, hematological malignancies, neurological or behavioral disorders, and migraine. Metabolites produced by the gut microbiome have been shown to influence the gut–brain axis. The use of probiotics as a dietary supplement may reduce the number and severity of migraine episodes. Dietary strategies can affect the course of migraines and are a valuable tool for improving migraine management. With fecal microbiota transplantation, gut microbial restoration is more effective and more durable. Changes after fecal microbiota transplantation were studied in detail, and many data help us to interpret the successful interventions. The microbiological alteration of the gut microflora can lead to normalization of the inflammatory mediators, the serotonin pathway, and influence the frequency and intensity of migraine pain. LA - English DB - MTMT ER - TY - JOUR AU - Rózsa, Annamária AU - Gyulai, Rolland Péter AU - Szabó, Ilona AU - Dezsőné, Siba Krisztina AU - Kappéter, Ágnes AU - Sütő, Gábor TI - HIV fertőzés felnőttkori Still-betegség hátterében JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 96 PY - 2020 IS - 2 SP - 104 EP - 107 PG - 4 SN - 0006-7768 DO - 10.7188/bvsz.2020.96.2.7 UR - https://m2.mtmt.hu/api/publication/31385145 ID - 31385145 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Vigvári, Szabolcs József AU - Vincze, Áron AU - Solt, Jenő AU - Sipos, Dávid AU - Feiszt, Zsófia AU - Kovács, Beáta AU - Kappéter, Ágnes AU - Péterfi, Zoltán TI - Experiences with fecal microbiota transplantation in Clostridium difficile infections via upper gastrointestinal tract JF - ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA J2 - ACTA MICROBIOL IMMUNOL HUNG VL - 66 ET - 0 PY - 2019 IS - 2 SP - 179 EP - 188 PG - 10 SN - 1217-8950 DO - 10.1556/030.65.2018.051 UR - https://m2.mtmt.hu/api/publication/30362752 ID - 30362752 AB - Dramatic changes in the epidemiology of Clostridium difficile infections have been reported from the western world in the past decade. The proportion of severe cases is significantly elevating and clinicians now have to contend with the problem of additional and more frequent episodes of recurrences including an upward trend in the mortality rate. This situation led us to investigate the possibility of the fecal microbiota transplantation (FMT). An amount of 100 ml of fecal microbiota solution was instilled into a nasojejunal (NJ) tube in 16 cases and into a nasogastric (NG) tube in 44 cases. In all of the cases, where the solution was instilled via nasojejunal tubes, the symptoms resolved within 24 h. We did not note any recurrences in this group. When the material was flushed in through nasogastric tubes, the symptoms resolved in 39 (88.64%) cases within 24 h. In this group, we have experienced a recurrent episode of C. difficile infection in five (11.36%) cases. Three of them were cured with a second transplantation. We have found that in our practice the upper gastrointestinal tract methods had the primary cure rate of 91.67%, whereas the secondary cure rate is 96.67%. When we compared the NJ and NG methods, we have found that the differences in the outcomes are not significant statistically (p = 0.3113 using Fisher's exact probability test). In conclusion, FMT proved to be very effective, particularly in recurrent infections and in cases where conventional treatment had failed. LA - English DB - MTMT ER - TY - JOUR AU - Vigvári, Szabolcs József AU - Sipos, Dávid AU - Solt, Jenő AU - Vincze, Áron AU - Kocsis, Béla AU - Nemes, Zsuzsanna AU - Kappéter, Ágnes AU - Feiszt, Zsófia AU - Kovács, Beáta AU - Péterfi, Zoltán TI - Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients JF - ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA J2 - ACTA MICROBIOL IMMUNOL HUNG VL - 66 PY - 2019 IS - 1 SP - 69 EP - 78 PG - 10 SN - 1217-8950 DO - 10.1556/030.64.2017.042 UR - https://m2.mtmt.hu/api/publication/3304835 ID - 3304835 N1 - Department of Infectious Diseases, 1st Department of Internal Medicine, University of Pécs, Pécs, Hungary Department of Gastroenterology, 1st Department of Internal Medicine, University of Pécs, Pécs, Hungary Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary Cited By :10 Export Date: 23 April 2024 Correspondence Address: Vigvári, S.; Department of Infectious Diseases, Hungary; email: szabolcs.vigvari@gmail.com AB - Faecal microbiota transplantation (FMT) has been reported to be effective in treating relapsing of refractory Clostridium difficile infections, although some practical barriers are limiting its widespread use. In this study, our objective was to evaluate the rate of resolution of diarrhea following administration of lyophilized and resolved FMT via a nasogastric (NG) tube. We recruited 19 patients suffered from laboratory-confirmed C. difficile infection. Each of them was treated by lyophilized and resolved inoculum through a NG tube. One participant succumbed following the procedure due to unrelated diseases. Out of 18 cases, 15 patients reportedly experienced a resolution of the symptoms. One patient was treated with another course of antibiotics, and two of the non-responders were successfully retreated with another course of FMT utilizing a lyophilized inoculum. Notably, no significant adverse activities were observed. In accordance to our clinical experiences, a patient will likely benefit from FMT treatment including lyophilized inoculum. LA - English DB - MTMT ER - TY - JOUR AU - Vigvári, Szabolcs József AU - Sipos, Dávid AU - Kappéter, Ágnes AU - Feiszt, Zsófia AU - Kovács, Beáta AU - Péterfi, Zoltán TI - Risk factors for Clostridium difficile infections in Baranya County, Southern Hungary JF - ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA J2 - ACTA MICROBIOL IMMUNOL HUNG VL - 65 PY - 2018 IS - 2 SP - 183 EP - 192 PG - 10 SN - 1217-8950 DO - 10.1556/030.65.2018.023 UR - https://m2.mtmt.hu/api/publication/3360067 ID - 3360067 N1 - Cited By :2 Export Date: 23 April 2024 Correspondence Address: Vigvári, S.; First Department of Internal Medicine, Hungary; email: szabolcs.vigvari@gmail.com AB - In the past decade, Clostridium difficile infections (CDIs) have become a major public health challenge. Their epidemiology has radically changed with a significant rise in the number of cases and an increase in severe episodes. Recurrence and failure of conventional treatments are very common. Furthermore, a spread of CDI has emerged in general population without the usual risk factors (unexposed to antibiotic treatment, young people, etc.). The conventional treatments (metronidazole and vancomycin) are still effective and are the first-line antibiotics with new recommendations. New therapeutic strategies are now available. Recent studies show a better efficacy of vancomycin compared with metronidazole for severe episodes. Fidaxomicin is a novel antibiotic drug with an efficacy similar to vancomycin and a lower risk of recurrence. Finally, for relapsing forms, fecal microbiota transplantation (FMT) seems to be the best option. We determined risk factors for CDI among patients treated at the infectious diseases ward of our hospital in Pecs. The study included 886 patients with CDI from 2009 to 2014. The average number of recurrent episodes was 2.16 and the proportion of severe cases was 66%. Among our patients, 726 (82%) had taken antibiotics and 769 (86.8%) had been hospitalized in the prior 3 months before developing CDI. We have found that prior statin use could be a significant risk factor of CDI (OR: 1.7765, 95% CI: 1.3966-2.2597, p < 0.0001). Finally, we present the comparative efficacy of different types of treatment (metronidazole, vancomycin, fidaxomicin, and FMT). LA - English DB - MTMT ER - TY - JOUR AU - Gyimesi, A AU - Bator, A AU - Gorog, P AU - Telegdy, E AU - Szepes, E AU - Kappéter, Ágnes AU - Gyulai, Rolland Péter AU - Lengyel, Zsuzsanna TI - Cutaneous Cryptococcus albidus infection. JF - INTERNATIONAL JOURNAL OF DERMATOLOGY J2 - INT J DERMATOL VL - 56 PY - 2017 IS - 4 SP - 452 EP - 454 PG - 3 SN - 0011-9059 DO - 10.1111/ijd.13576 UR - https://m2.mtmt.hu/api/publication/3186390 ID - 3186390 N1 - Case Reports LA - English DB - MTMT ER - TY - JOUR AU - Vigvári, Szabolcs József AU - Nemes, Zsuzsanna AU - Vincze, Áron AU - Solt, J AU - Sipos, Dávid AU - Feiszt, Zsófia AU - Kappéter, Ágnes AU - Kovács, Beáta AU - Péterfi, Zoltán TI - Clostridium difficile-fertőzések széklettranszplantációval való kezelése során nyert tapasztalataink JF - ORVOSI HETILAP J2 - ORV HETIL VL - 155 PY - 2014 IS - 44 SP - 1758 EP - 1762 PG - 5 SN - 0030-6002 DO - 10.1556/OH.2014.30020 UR - https://m2.mtmt.hu/api/publication/2765530 ID - 2765530 N1 - Export Date: 27 January 2024; CODEN: ORHEA AB - INTRODUCTION: During the past years a dramatic change has been observed in the epidemiology of Clostridium difficile infections. AIM: The aim of the authors was to investigate the possibility of the fecal microbiota transplantation and study differences, if any, in the success rate of the two different upper gastrointestinal tract method. METHOD: 100 ml of fecal microbiota solution was instilled via a nasoduodenal tube in 15 cases and a nasogastric tube in 15 cases. The authors defined the primary cure rate as the percentage of cases in which the symptoms disappeared without recurrence within 6 weeks after the first fecal microbiota transplantation, while secondary cure rate was calculated as the percentage of cases in which the symptoms resolved after the second fecal microbiota transplantation. RESULTS: It was found that fecal microbiota transplantation applied via the nasoduodenal tube resulted in a 100% primary cure rate. With the use of the nasogastric tube, the primary and secondary cure rate were 80% and 93.3%, respectively. Fecal microbiota transplantation via the upper gastrointestinal tract was found to have an overall primary cure rate of 90.0% and a secondary cure rate of 96.7%. CONCLUSIONS: Fecal microbiota transplantation proved to be very effective, particularly in recurrent infections and cases where conventional treatment failed. Orv. Hetil., 2014, 155(44), 1758-1762. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kappéter, Ágnes TI - Gyermekkori húgyúti fertőzések JF - INFEKCIÓ ÉS INFEKCIÓKONTROLL J2 - INFEKCIÓ ÉS INFEKCIÓKONTROLL VL - 4 PY - 2007 IS - 2 SP - 17 EP - 21 PG - 5 SN - 1786-0032 UR - https://m2.mtmt.hu/api/publication/1490751 ID - 1490751 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kappéter, Ágnes TI - Herpes encephalitis JF - INFEKCIÓ ÉS INFEKCIÓKONTROLL J2 - INFEKCIÓ ÉS INFEKCIÓKONTROLL VL - 3 PY - 2006 IS - 2 SP - 123 EP - 126 PG - 4 SN - 1786-0032 UR - https://m2.mtmt.hu/api/publication/1490770 ID - 1490770 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kappéter, Ágnes TI - Herpes labialis JF - INFEKCIÓ ÉS INFEKCIÓKONTROLL J2 - INFEKCIÓ ÉS INFEKCIÓKONTROLL VL - 2 PY - 2005 IS - 5 SP - 399 EP - 401 PG - 3 SN - 1786-0032 UR - https://m2.mtmt.hu/api/publication/1490780 ID - 1490780 LA - Hungarian DB - MTMT ER -